MK-1775, a specific Wee1 inhibitor, has been tested as a possible therapeutic option in sarcomas; e.g., Wee1 inhibition has been shown to sensitize osteosarcoma cells in vitro to chemotherapy or radiation at clinically feasible concentrations15,16,23. Here, WEE1 is linked to sarcoma.